BDKRB2抗体—艾普蒂

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane: HUVEC cell lysate, Primary antibody: P10711(BDKRB2 Antibody) at dilution 1/650, Secondary antibody: Goat anti rabbit IgG at 1/5000 dilution, Exposure time: 10 minutes    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human tonsil tissue using P10711(BDKRB2 Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

The B2 bradykinin receptor (BDKRB2) is a G protein-coupled receptor that binds bradykinin, a peptide involved in inflammation, pain perception, vasodilation, and vascular permeability. It is constitutively expressed in various tissues, including vascular endothelium, smooth muscle, and nervous system cells. BDKRB2 activation triggers signaling pathways (e.g., IP3. NO, MAPK) regulating blood pressure, edema, and pain responses. Dysregulation of BDKRB2 is linked to hereditary angioedema, hypertension, diabetic complications, and chronic inflammatory conditions.

BDKRB2 antibodies are immunological tools used to detect, quantify, or inhibit the receptor in research and diagnostics. They are commonly applied in techniques like Western blotting, immunohistochemistry, and ELISA to study BDKRB2 expression patterns, cellular localization, and receptor dynamics in disease models. Some antibodies block ligand binding or receptor activation, aiding functional studies of bradykinin pathways. Clinically, BDKRB2-targeting antibodies or antagonists have been explored for treating angioedema and inflammatory disorders, though therapeutic applications remain largely experimental. The development of selective BDKRB2 antibodies also supports drug discovery efforts aimed at modulating bradykinin-mediated pathologies while minimizing cross-reactivity with related receptors like BDKRB1.